natgillin/translations-raw huggingface dataset:
9 Quai Jules Guesde 94403 Vitry-sur-Seine France
9 Quai Jules Guesde 94403 Vitry-sur-Seine Francuska
9 SPECIAL STORAGE CONDITIONS
9 POSEBNE MJERE ČUVANJA
9 times per year).
9 puta godišnje).
9 to 15-year-old boys
Dječaci u dobi od 9 do 15 godina
9 to 15-year-old girls
Djevojčice u dobi od 9 do 15 godina
9 to 15-years of age girls
Djevojčice u dobi od 9 do 15 godina
9 to 17
9 do 17
9 to 17 years
9 do 17 godina
9 to 17 years N = 51 N = 34
9 do 17 godina N = 51 N = 34
9 to < 16
9 do < 16
9 to and including 14 years*
9 do uključivo 14 godina
9 – 17 years
9 – 17 godina
9 – 17 years 3 – 8 years 6 – 35 months
9 – 17 godina 3 – 8 godina 6 – 35 mjeseci
9% (2 to 17%)
9% (2 do 17%)
9% of patients receiving Taltz developed neutropenia.
U 9% bolesnika koji su primali Taltz razvila se neutropenija.
9% p = 0.009
31% p = 0,002
9) Adverse events were experienced by 88% of Pegasys-treated patients as compared with 53% of patients in the lamivudine comparator group, while 6% of the Pegasys-treated and 4% of the lamivudine-treated patients experienced serious adverse events during the studies.
Nuspojave su se pojavile u 88% bolesnika liječenih lijekom Pegasys u usporedbi s 53% bolesnika u usporednoj skupini liječenoj lamivudinom, dok su se u 6% bolesnika liječenih lijekom Pegasys i 4% bolesnika liječenih lamivudinom tijekom ispitivanja pojavile ozbiljne nuspojave.
9,000 IU/0.9 ml
9000 IU/0,9 ml
9- to 15-Year-Old Boys
Dječaci u dobi od 9 do 15 godina
9- to 15-Year-Old Girls (Protocols 016 and 018)
Djevojčice 9-15 godina (Protokoli 016 i 018)
9-16 micrograms
9-16 mikrograma
9.0 g/day
9,0 g/dan
9.00 (3.97, 20.41)
9,00 (3,97; 20,41) p<0,0001
9.00 (3.97, 20.41) p<0.0001
9,00 (3,97; 20,41) p<0,0001
9.1 (5.9 - 13.2)
ocijeniti odgovor)
9.2 % of the patients entered the study with locally recurrent disease stage as had been evaluated at baseline.
U studiju je ušlo 9,2 % bolesnika s lokalno rekurentnim stadijem bolesti kao što je procijenjeno na početku ispitivanja.
9.27
(n=126)
9.2d (7.4, NR)
9,2d (7,4, NP)
9.3 months, HR = 0.77, 97.5% CI = [0.63; 0.94]; p-value = 0.0026.
Hazard Ratio, HR) = 0,89; 97,5% CI = [0,73; 1,08]; p-vrijednost = 0,1871.
9.3% versus 1.3%; non-HDL-cholesterol 2.2% and 4.4% versus 0.7%; triglycerides 2.4% and 0.0% versus 7.6%.
kolesterol 5,7% i 9,3% naspram 1,3%; ne HDL kolesterol 2,2% i 4,4% naspram 0,7%; trigliceride 2,4% i 0,0% naspram 7,6%.
9.4 (6.6, 12.9)
2,06f (1,41; 3,00)
9.4 (7.3-13.2) (4-week schedule)
9,4 (7,3-13,2) (4-tjedni raspored)
9.5 m vs 5.5 m
9,5 m vs 5,5 m
9.5 m vs 6.3 m
9,5 m vs 6,3 m
9.5 mg/24 h
10 cm2
9.5 mg/24 h N = 251
9,5 mg/24 h N=251
9.5 mg/24 h N = 251
rivastigminom
9.5 mg/24 h transdermal patch
9,5 mg/24 h transdermalni flaster
9.5 mg/24 h transdermal patch rivastigmine
9,5 mg/24 h transdermalni flaster rivastigmin
9.5 mg/24 h transdermal patch).
9,5 mg/24 h transdermalni flaster).
9.5 mg/24h
mg/24H
9.57 [3.39, 15.75]; P = 0.0026 c
9,57 [3,39, 15,75]; P = 0,0026 c
9.63 months in the Cyramza plus paclitaxel arm and 7.36 months in the placebo plus paclitaxel arm.
9,63 mjeseca u skupini liječenoj lijekom Cyramza plus paklitakselom te 7,36 mjeseci u skupini koja je primala placebo plus paklitaksel.
9.7 (8.3, NE)
9,7 (8,3, NP)
9.9 - 13.0 g/m2/day in children weighing more than 20 kg, adolescents and adults.
9,9 - 13,0 g/m2/dan za djecu koja teže više od 20 kg, adolescente i odrasle.
9.9 - 13.0 g/m2/day in children weighing more than 20 kg, adolescents and adults.
9,9 - 13,0 g/m2/dan za djecu težine veće od 20 kg, adolescente i odrasle.
9.91
(N=14)
9.98 mg lactose(as monohydrate) in each 600 mg daily dose.
9,98 mg laktoze (u obliku hidrata) u jednoj dnevnoj dozi od 600 mg.
90 (3 bottles of 30) film-coated tablets
90 (3 boce od 30) filmom obloţenih tableta
90 (3 bottles of 30) film-coated tablets
90 (3 boce od 30) filmom obloženih tableta
90 (3 bottles of 30) film-coated tablets
90 (3 boce po 30) filmom obloženih tableta
90 (3 bottles of 30) film-coated tablets
90 (3 boce s 30) filmom obloženih tableta
90 (3 bottles of 30) film-coated tablets 90 (3 bottles of 30) tablets
90 (3 bočice od 30) filmom obloženih tableta 90 (3 bočice od 30) tableta
90 (3 x 30 x 1) capsules (unit dose) (multipack) +
90 (3 x 30 x 1) kapsula (jedinično pakovanje) (višestruko pakovanje)
90 (3 x 30 x 1) tablets (unit dose) (bundle multipack)
90 (3 x 30 x 1) tableta (jedinična doza) (višestruko pakovanje paket)
90 (3 x 30 x 1) tablets (unit dose) (carton multipack)
90 (3 x 30 x 1) tableta (jedinična doza) (višestruko pakovanje kutija)
90 (3 x 30) ampoules (multipack)
90 (3 x 30) ampula (višestruko pakiranje)
90 (3 x 30) AMPOULES WITH 2 ML
90 (3 x 30) AMPULA S 2 ML
90 (3 x 30) capsules
90 (3x 30) kapsula
90 (3 x 30) sachets (multipack)
90 (3 x 30) vrećica (višestruko pakovanje)
90 (3 x 30) sachets (multipack)
90 (3 x 30) vrećice (višestruko pakovanje)
90 (3 x 30) tablets (multipack)
90 (3 x 30) tableta (višestruko pakovanje)
90 (3x30) ampoules
90 (3x30) ampula
90 ampoules
90 ampula
90 AMPOULES WITH 2 ML
90 AMPULA S 2 ML
90 capsules
90 kapsula
90 days after start of treatment, 84% (92 out of 109) of Zycortal-treated dogs had improved clinical signs and normal sodium and potassium blood levels.
90 dana nakon početka terapije, 84% (92 od 109) pasa liječenih VMP-om Zycortal imalo je poboljšane kliničke znakove i normalne koncentracije natrija i kalija.
90 film-coated tablets, together with one plastic canister containing a molecular sieve desiccant.
90 filmom obloženih tableta i jedan plastični spremnik s molekularnim sitom kao sredstvom za sušenje.
90 film-coated tablets.
90 filmom obloženih tableta.
90 hard capsules: bottle
90 tvrdih kapsula: boca
90 hard capusles
90 tvrdih kapsula
90 Imatinib 400 mg once daily (n = 283)
90 Imatinib 400 mg 1xdan (n = 283)
90 mcg/0.5 ml
90 μg/0,5 ml
90 mg tablet: blue, pentagonal (major axis 9.7 mm, minor axis 9.5 mm), shallow-convex, debossed with “OTSUKA” and “90” on one side
Tableta od 30 mg: plava, okrugla (promjer: 8 mm), blago konveksna, s utisnutim “OTSUKA” i “30” na jednoj strani.
90 mg twice daily
90 mg dva puta dnevno
90 ml or 100 ml*
90 ml ili 100 ml
90 ml oral solution
90 ml oralne otopine
90 pouches
90 Vrećica
90 prolonged-release tablets
90 tableta s produljenim oslobaĎanjem
90 single-dose containers
90 jednodoznih spremnika
90 soft capsules
90 mekih kapsula
90 tablets
15 tableta
90 tablets
90 tablet
90 tablets
90 tablete
90 tablets (PVC/PCTFE blisters)
90 tableta (PVC/PCTFE blisteri)
90 tablets: EU/1/08/469/004
90 tableta: EU/1/08/469/004
90 tablets: EU/1/08/469/009
90 tableta: EU/1/08/469/009
90 tablets: EU/1/08/469/014
90 tableta: EU/1/08/469/014
90 tablets: EU/1/08/469/019
90 tableta: EU/1/08/469/019
90 tablets: EU/1/08/469/024
90 tableta: EU/1/08/469/024
90 tablets: EU/1/08/480/020
90 tableta: EU/1/08/480/020
90 tablets: EU/1/10/632/006
90 tableta: EU/1/10/632/006
90 tablets: EU/1/10/632/013
90 tableta: EU/1/10/632/013
90 tablets: EU/1/10/632/020
90 tableta: EU/1/10/632/020
90 tablets: EU/1/11/721/006
90 tableta: EU/1/11/721/006
90 tablets: EU/1/11/721/013
90 tableta: EU/1/11/721/013
90 tablets: EU/1/11/721/020
90 tableta: EU/1/11/721/020
90 tablets: EU/1/11/723/006
90 tableta: EU/1/11/723/006
90 tablets: EU/1/11/723/013
90 tableta: EU/1/11/723/013
90 tablets: EU/1/11/723/020
90 tableta: EU/1/11/723/020
90 tablets: five transparent blisters of 18 tablets each.
90 tableta: pet prozirnih blistera, svaki s 18 tableta.
90 transdermal patches
90 transdermalnih flastera
90 x 1 capsules
90 x 1 kapsula
90 x 1 film-coated tablet Bottle pack: 30 film-coated tablets
90 x 1 filmom obložena tableta Pakovanje u boci: 30 filmom obloženih tableta
90 x 1 film-coated tablet; 9 blister cards of 10 x 1 film-coated tablet each in Alu/Alu perforated unit dose blisters.
90 × 1 filmom obloženu tabletu; 9 blistera s 10 × 1 filmom obloženom tabletom, svaka u Al/Al perforiranim blisterima djeljivima na jedinične doze
90 x 1 film-coated tablets
90 x 1 filmom obloženih tableta
90 x 1 film-coated tablets.
90 x 1 filmom obložena tableta.
90 x 1 tablet (unit dose)
90 x 1 tableta (jedinična doza)
90 x 1 tablets
90 x 1 tableta
90 x 1 tablets
tableta
90 x 1 tablets (unit dose)
90 x 1 tableta (jedinična doza)
90 x 1 tablets (unit dose)
90 x 1 tableta (jedinične doze)
90 g PRE-FILLED SYRINGE
90 µg NAPUNJENA ŠTRCALJKA
90% of patients were CTCAE grade 0 at baseline, and 10% were CTCAE grade 1 at baseline.
Na početku liječenja je 90% bolesnica imalo vrijednost 0. stupnja prema CTCAE kriterijima, a 10% njih imalo je vrijednost 1. stupnja.
90, 98, 112 and 196 tablets.
98, 112 ili 196 tableta.
90.5 days
90,5 dana
900 mg at week 3; then 900 mg every 2 weeks
900 mg u 3. tjednu; potom 900 mg svaka 2 tjedna
900 mg dose for Cycle 1 Day 1 (continued) or Day 2.
1. ciklusa (nastavak) ili 2. dan 1. ciklusa.
9000 IU/0.9 ml
8000 IU/0,8 ml
9000 IU/0.9 ml
9000 IU/0,9 ml
9000 microgram (mcg/ml) for patients under 2 years of age
9000 mikrograma (μg/ml) za bolesnike ispod 2 godine starosti
90429 Germany
90429 Nürnberg Njemačka
90650 Oulu Finland
90650 Oulu Finska
90x1 film-coated tablets
100x1 filmom obloženih tableta
90x1 film-coated tablets
90x1 filmom obloženih tableta
90x1 tablets (unit dose)
90x1 tableta (jedinična doza)
90° angle
kut od 90°
91192 GIF-SUR-YVETTE Cedex, FRANCE
91192 GIF-SUR-YVETTE Cedex, FRANCUSKA
92 micrograms
92 mikrograma
92 micrograms /
92 mikrograma /
92 patients treated with docetaxel in combination with trastuzumab.
92 bolesnika koji su primali docetaksel u kombinaciji s trastuzumabom,
92 subjects in the vaccine group had immunogenicity data at the [M107- M113] interval after the first vaccine dose with a median follow-up of 8.9 years.
92 ispitanica iz grupe cijepljenih su imale podatke o imunogenosti u intervalu od 107. do 113. mjeseca nakon prve doze cijepljenja, s medijanom praćenja od 8,9 godina.
92.8% to 98.6%
92,8 % do 98,6
92.9% to 98.0%
92,9 % do 98,0
92110 Clichy France
SE-114 57 Stockholm
92150 Suresnes
2150 Suresnes
92250 La Garenne Colombes
Paris La Défense
92800 - Puteaux France
92800 - Puteaux Francuska
92800 - Puteaux France
92800 – Puteaux Francuska
93% (149/160)
HCV genotip 1a
93.2 %
(NP; NP)
93.2 % of patients received ASA concomitantly plus thienopyridine treatment and 6.8 % ASA only.
93,2 % bolesnika istodobno je primalo ASA uz dodatak tienopiridina, a 6,8 % samo ASA.
93055 Regensburg Germany
93055 Regensburg Njemačka
93055 Regensburg Germany
93055 Regensburg Njemačka‌
94 (83.9%) patients randomised to the BAT arm crossed over to ruxolitinib treatment at Week 32 or after, limiting the comparison between the two arms after Week 32.
94 (83,9%) bolesnika randomiziranih u NDT skupinu prešlo je na liječenje ruksolitinibom u 32. tjednu ili kasnije, što je ograničilo usporedbu između dviju skupina nakon 32. tjedna.
94.1 (11.42)
(N=123)
94.3% to 98.9%
94,3 % do 98,9
94.3)
N=76
94.42% B)
94,42% B)
94.9 (77.7 to 117.0)
94,9 (77,7 do 117,0)
94250 Gentilly France
94250 Gentilly Francuska
95 % CI = 0.64-0.96).
95% CI = 0,64 – 0,96).
95 % CI for median
95 % CI za medijan
95 % CI for median
95% CI za medijan
95 % CI for overall
95% CI za ukupan odgovor
95 % Confidence interval
Interval pouzdanosti 95
95 % confidence interval
Interval puzdanosti95
95 % of dogs had returned to normal plasma testosterone levels within 2.5 years of implantation.
95% pasa vratilo je normalne vrijednosti testosterona u 2,5 godine od implantacije.
95 % two-sided CI on the treatment difference (Eurartesim - Comparator); p-value
95% dvostrani CI za razliku liječenja (Eurartesim – usporedni lijek); p-vrijednost
95 (35.4 %) p<0.028. No signs of any increase adverse effects were noted in this study.
U tom ispitivanju nije zabilježeno povećanje nuspojava.
95 mg/23.75 mg modified-release hard capsule
Tvrde kapsule s prilagođenim oslobađanjem od 95 mg/23,75 mg
95 mg/23.75 mg modified-release hard capsules
Tvrde kapsule s prilagođenim oslobađanjem od 95 mg/23,75 mg
95 ml oral solution (1 bottle) Oral syringe
95 ml oralne otopine (1 boca) Oralna štrcaljka
95%
CI 95
95% (84/88)
PEG-IFN+RBV
95% CI
(%)
95% CI
p-vrijednost
95% CI (0.30, 0.60) p-value < 0.0001
95% CI (0,30; 0,60) p-vrijednost < 0,0001
95% CI for Difference in Response Rates4
95% CI za razliku u stopama odgovora4
95% CI for Hazard ratio
95% CI za omjer hazarda
95% CI for hazard ratio (0.4316 to 0.6430) p-valuea <0.0001
95% CI za omjer rizika (0,4316 do 0,6430) p-vrijednosta < 0,0001
95% CI for hazard ratio (0.6730 to 1.0013) p-value a 0.0510
95% CI za omjer rizika (0,6730 do 1,0013) p-vrijednosta 0,0510
95% CI for median
95% CI za medijan
95% CI for median (days)
95% CI za medijan (dani)
95% CI for one sample binomial using Pearson-Clopper method.
95% CI za binomni test na jednom uzorku primjenom Pearson-Clopperove metode.
95% CI for Response Rates3
95% CI za stope odgovora3
95% CI of Difference (p-value)
Razlika u srednjoj vrijednosti najmanjih kvadrata (SE) 95% CI razlike (p-vrijednost)
95% CI of mean**
95% CI srednje vrijednosti
95% CI of ORR
95% CI od ORR
95% CI of Rate5
95% CI stope5
95% CI: 3.8, 24.6
1,51 (0,35; 6,85)
95% CI: 6.2, 32.0
95% CI: 3,8; 24,6
95% CIa, b
95%-tni CIa, b
95% CL
95% CI
95% Confidence Interval
95 % interval pouzdanosti
95% Confidence Interval
95%-tni interval pouzdanosti
95% Confidence Interval
Interval pouzdanosti 95
95% confidence interval
Inteval pouzdanosti 95
95% confidence interval for the for the difference in proportions
95%-tni interval pouzdanosti za razliku u udjelima
95% confidence interval for the hazard ratio
95%-tni interval pouzdanosti za omjer hazarda
95% Confidence Interval1
95%-tni interval pouzdanosti1
95% confidence intervals
95% intervali pouzdanosti
95% confidence intervals
95%-tni intervali pouzdanosti
95% of R155K+V36M were undetectable by population sequencing.
R155K, 92% A156S, 96% I/V170A, 77% R155K+T54S i 95% R155K+V36M.
95% of the dose is excreted in the urine as drug and metabolites.
95% doze izlučuje se mokraćom u nepromijenjenom obliku i u obliku metabolita.
95% two-sided CI on the treatment difference (Eurartesim - Comparator); p-value
95% dvostrani CI za razliku liječenja (Eurartesim – usporedni lijek); p-vrijednost
95-200 Pabianice Poland
95-200 Pabianice Poljska
95.3% CI (%)
95,3% CI (%)
95.9% to 99.9%
95,9 % do 99,9
96 (4 x 24 x 1)
96 (4 x 24 x 1) kapsula
96 (4x24x1) capsules (unit
96 (4x24x1) kapsula
96 capsules
96 kapsula
96 gastro-resistant tablets
96 želučanootpornih tableta
96 hours after the administration of Foscan, the treatment site is to be illuminated with light at 652 nm from an approved laser source.
Kada od primjene Foscana protekne 96 sati, mjesto liječenja obasjava se svjetlošću valne duljine od 652 nm iz odobrenog laserskog izvora.
96 to 114
96 do 114
96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin) (see section 4.5).
96% beta blokatori, 33% antagonisti kalcijevih kanala diltiazem i verapamil i 4% digoksin) (vidjeti dio 4.5).
96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin).
96% beta blokatori, 33% blokatori kalcijevih kanala diltiazem i verapamil i 4% digoksin).
96% of subjects (64/67) still had protective antibody levels (PRNT50≥1:10), with a GMT of 148 (95%CI: 107; 207).
96 % ispitanika (64/67) još je imalo zaštitne razine protutijela (PRNT50 ≥ 1:10), uz GMT 148 (95 % CI: 107; 207).
96.4% (92.5; 98.2%)
Degareliks 240/80 mg N=207
96.5% CI
96,5% CI
96.85% CI (0.43, 0.81) p-value 0.0002
96,85% CI (0,43; 0,81)
97.5 % and 97.2 % with geometric mean titres of 214 and 297 IU/l, respectively.
214 IU/l i 97,2% sa srednjim geometrijskim titrom od 297 IU/l.
97.5% confidence intervals are used for the primary efficacy endpoints (overall SVR12 rate); 95% confidence intervals are used for additional efficacy endpoints (SVR12 rates in HCV genotype 1a and 1b-infected subjects).
Za primarnu mjeru ishoda za djelotvornost (ukupna stopa SVR12) koriste se intervali pouzdanosti od 97,5%; za dodatne mjere ishoda za djelotvornost (stope SVR12 u ispitanika s infekcijom HCV-om genotipa 1a i 1b) koriste se intervali pouzdanosti od 95%.
97/100 ut SVR1
Sažetak dizajna ispitivanja
9785-CL-0222 (TERRAIN) study (chemotherapy-naïve patients)
Ispitivanje 9785-CL-0222 (TERRAIN) (bolesnici koji ranije nisu primali kemoterapiju)
98 (2 x 49 x 1) tablets (unit dose) (multipack)
98 (2 x 49 x 1) tableta (pakovanje s jediničnim dozama) (višestruko pakovanje)
98 (2 x 49) capsules
98 (2 kutije x 49)
98 (2 x 49) tablets (multipack)
98 (2 x 49) tableta (višestruko pakovanje)
98 coated tablets
98 obloženih tableta
98 film-coated tablets
50 filmom obloženih tableta 98 filmom obloženih tableta
98 hard capsules
98 tvrdih kapsula
98 tablets (2x49, PA/Alu/PVC blisters)
98 tableta (2x49, PA/Al/PVC blisteri)
98 tablets (2x49x1, PVC/PCTFE single-unit-dose blisters)
98 tableta (2x49x1, PVC/PCTFE blisteri djeljivi na jedinične doze)
98 tablets (PVC/PCTFE blisters)
98 tableta (PVC/PCTFE blisteri)
98 tablets.
98 tableta.
98 tablets: EU/1/08/480/006
98 tableta: EU/1/08/480/006
98 tablets: EU/1/10/632/007
98 tableta: EU/1/10/632/007
98 tablets: EU/1/10/632/014
98 tableta: EU/1/10/632/014
98 tablets: EU/1/10/632/021
98 tableta: EU/1/10/632/021
98 tablets: EU/1/11/721/007
98 tableta: EU/1/11/721/007
98 tablets: EU/1/11/721/014
98 tableta: EU/1/11/721/014
98 tablets: EU/1/11/721/021
98 tableta: EU/1/11/721/021
98 tablets: EU/1/11/723/007
98 tableta: EU/1/11/723/007
98 tablets: EU/1/11/723/014
98 tableta: EU/1/11/723/014
98 tablets: EU/1/11/723/021
98 tableta: EU/1/11/723/021
98 x 1 film-coated tablets
98 x 1 filmom obložena tableta
98 x 1 Film-coated tablets
98 x 1 filmom obloženih tableta.
98 x 1 film-coated tablets
98 × 1 filmom obložena tableta
98 x 1 Film-coated tablets.
98 x 1 filmom obloženih tableta.
98 x 1 tablet (unit dose)
98 x 1 tableta (jedinična doza)
98 x 1 tablets
98 x 1 tableta
98 x 1 tablets (unit
98 x 1 tableta
98 x 1 tablets (unit dose)
98 x 1 tableta (jedinična doza)
98.5
n/N
98.52% CI (0.57, 0.93) p-value 0.0018
98,52% CI (0,57; 0,93) p-vrijednost 0,0018
98.7%
Rubela (titar
980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom.
980 Great West Road, Brentford, Middlesex TW8 9GS, Ujedinjeno Kraljevstvo.
980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom
980 Great West Road Brentford, Middlesex, TW8 9GS Ujedinjeno Kraljevstvo
980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom
980 Great West Road, Brentford, Middlesex, TW8 9GS Ujedinjeno Kraljevstvo
99 % of patients (243/246) enrolled in the STS phase III study, including the 15 subjects, received anthracycline.
Devedeset i devet posto ispitanika (243/246) uključenih u STS ispitivanje faze III, uključujući 15 ispitanika, primalo je antracikline.
99 x 106 cells/l
99 x 106 stanica/l
99% (87/88)
47 % (207)a
99-300 Kutno Poland
99-300 Kutno Poljska
99.3%
Vremenska točka
99.4%
doze
99.79% CI (0.25, 0.73)
99,79% CI (0,25; 0,73)
995 patients comprised the intent-to-treat population.
Populacija koju se namjeravalo liječiti (engl. intent- to-treat, ITT) obuhvaćala je 995 bolesnika.
: Adverse reactions for which no frequency could be derived from clinical studies (i.e. where a specific adverse reaction was not observed in clinical trials but was reported post-marketing only) are indicated by an asterisk (*), and the frequency category has been calculated according to EU Guideline.
⃰: Nuspojave čija se učestalost nije mogla odrediti u kliničkim ispitivanjima (tj. kada specifične nuspojave nisu primjećene tijekom kliničkih ispitivanja već je izviješteno o njima samo nakon stavljanja lijeka u promet) označene su zvjezdicom (*), a kategorija učestalosti izračunana je prema EU smjernicama.
: Corrected for multiple comparisons and adjusted for stratification factors (stage of disease and region of treatment), based on evaluable patient population.
Korigirano za višestruku usporedbu i prilagođeno faktorima stratifikacije (stadij bolesti i regija liječenja) na osnovu podataka iz populacije bolesnika koji su se mogli procijeniti
:S25%
Antibiotici
:S25% (CYP3A4 enzyme induction)
(indukcija CYP3A4)
< 0.0001 (1-sided and 2-sided)
< 0,0001 (1-strano and 2-strano)
< 0.001
p- vrijednost
< 0.32 mmol/L (1.0 mg/dL) then Stribild should be discontinued.
< 0,32 mmol/l (1,0 mg/dl), primjenu Stribilda se mora prekinuti.
< 0.5 x 109/l), 12 % vs 5 %, and thrombocytopenia (< 20 x 109/l ), 9 % vs 3 %, in women vs men in the first cycle of therapy.
< 0,5 x 109/l) i trombocitopenije (< 20 x 109/l) stupnja 4 bila je viša u žena nego u muškaraca: 12% naspram 5% kod neutropenije i 9% naspram 3% kod trombocitopenije.
< 0.5 x 109/L, eltrombopag may be reinitiated at the previous effective dose.
< 9 g/dL ili ABN na < 0,5 x 109/L, liječenje eltrombopagom može biti ponovo započeto prethodnom učinkovitom dozom.
< 0.5  109/L
< 0,5  109/L
< 0.65 mmol/L [< 25 mg/dL]) have not yet been established.
< 0,65 mmol/L [< 25 mg/dL]) još nije ustanovljen.
< 1%, 0%, and 2% for patients receiving ledipasvir/sofosbuvir + ribavirin combination therapy for 8, 12 and 24 weeks, respectively.
< 1 %, 0 %, odnosno 2 % kod pacijenata koji su primali kombiniranu terapiju ledipasvirom/sofosbuvirom + ribavirin tijekom 8, 12 odnosno 24 tjedna.
< 1,500 but
< 1500 ali
< 1.0 x 109/L and/or platelets
i/ili trombociti <50 x 109/l
< 1.0 x 109/L and/or platelets
≥1,5 x 109/l i trombociti ≥75 x 109/l.
< 1.0 x 109/L and/or platelets
≥1,5 x 109/l i tromociti ≥75 x 109/l.
< 1.0 x 109/L and/or platelets
≥75 x 109/l
< 1.0 x 109/l and/or platelets < 50 x 109/l, repeat step 1 and resume Glivec at reduced dose of 300 mg.
1,5 x 109/l i trombociti 75 x 109/l. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 300 mg.
< 1.0 x 109/l and/or platelets < 50 x 109/l, repeat step 1 and resume Glivec at reduced dose of 400 mg.
1,5 x 109/l i trombociti 75 x 109/l. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 400 mg.
< 1/1,000)
Razdražljivost
< 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from available data).
< 1/1000), vrlo rijetko (< 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data).
<1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from available data).
< 1/1000); vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/1,000); very rare (< 1/10,000).
< 1/1000); vrlo rijetko (< 1/10000).
< 1/1,000); very rare (< 1/10,000).
<1/1000); vrlo rijetko (<1/10 000).
< 1/1,000); very rare (< 1/10,000); and not known (cannot be estimated from available data).
< 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000); i nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/10), uncommon ( 1/1000 to < 1/100) and not known (cannot be estimated from the available data).
Nuspojave su popisane po organskim sustavima i kategorijama učestalosti (vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i ≤ 1/100) i nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000).
< 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000).
< 1/100
≥1/10 000 i <1/1000
< 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
< 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
< 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (frequency cannot be estimated from the available data).
< 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).